Evidence analysisNovember 12, 2026Privacy & Data
Collaboration on artificial intelligence

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
Privacy & Data: Collaboration on Artificial Intelligence in European Medicines Regulation
What is established
The European Medicines Agency (EMA) actively collaborates with European and international partners to integrate artificial intelligence (AI) into the regulation of medicines. This cooperation aims to foster innovation while maintaining safety, transparency, and compliance with legal and ethical standards. EMA chairs the EU Agencies Network’s (EUAN) working group on AI, coordinating activities and knowledge sharing among multiple EU bodies until 2027.
Key partnerships include collaboration with the European Commission on implementing the EU AI Act and the upcoming pharmaceutical legislation, cooperation with the Heads of Medicines Agencies (HMA) Network, and engagement with international stakeholders through the International Coalition of Medicines Regulatory Authorities (ICMRA). EMA also works with the US Food and Drug Administration (FDA) to develop guiding principles for AI use in medicine development.
What the source claims
- EMA and its partners organize stakeholder workshops, assess AI use cases, and build AI skills within regulatory agencies to support responsible AI adoption.
- The EUAN working group, chaired by EMA, focuses on aligning AI governance, promoting AI literacy, and facilitating shared AI services across EU agencies.
- Collaboration with industry, academia, patients, and experts through the HMA’s AI-focused stakeholder group helps regulators understand emerging AI applications and industrial practices.
- International cooperation, including with ICMRA and FDA, supports regulatory convergence and the development of harmonized principles for AI deployment in medicines.
- EMA contributes to regulatory science by defining AI research priorities and monitoring developments through tools such as the AI Observatory.
What may be missing from the usual framing
The official communications primarily emphasize cooperative efforts, regulatory alignment, and responsible innovation, but they do not deeply address several potentially relevant privacy and data-related issues:
- Data privacy and protection challenges: While transparency and legal compliance are mentioned, specific risks related to patient data privacy in AI systems, including data sharing and cross-border flows, are not elaborated upon.
- Bias and fairness: There is little detail on how EMA and partners intend to identify and mitigate biases within AI algorithms that could impact regulatory decisions or patient outcomes.
- Transparency and explainability: The summary does not clarify the standards or requirements for AI transparency to enable accountability in medicinal regulation.
- Power dynamics and influence: The source does not discuss how the involvement of pharmaceutical and medical device industry associations in stakeholder groups might affect regulatory independence or data governance frameworks.
- Potential surveillance or data exploitation: The framing lacks discussion on how AI integration might implicate concerns over surveillance or commercial exploitation of health data beyond regulation.
Competing evidence or uncertainty
Evidence directly from this EMA source is insufficient to assess controversies or disagreements regarding the use of AI in medicines regulation, particularly concerning privacy or ethical complexity.
Independent analyses or civil society critiques might question whether regulatory partnerships with industry risk conflicts of interest or insufficient protection of patient data. Similarly, concerns exist internationally about the adequacy of AI governance frameworks for health data, but the extent to which these apply specifically to EMA initiatives is not clarified here.
Further, there is uncertainty about how detailed and enforceable the “guiding principles” co-developed with the FDA are, or how they address data rights and transparency in practice.
Why it matters
The integration of AI in medicines regulation has the potential to accelerate innovation, enhance safety monitoring, and improve access to new treatments. However, because regulation involves sensitive personal health data and impacts public trust, robust privacy protections, transparency, and ethical governance are essential to prevent misuse or unintended harms.
How EMA, together with EU and international partners, handles data privacy, algorithmic fairness, and regulatory transparency will influence not only public health outcomes but also individual rights and confidence in health systems. The balance between fostering technological innovation and safeguarding privacy and ethics is a core challenge.
What to verify next
- Examine the original EMA documentation and updates concerning their AI governance frameworks, especially regarding privacy and data protection safeguards.
- Review the EU AI Act and related pharmaceutical legislation to assess concrete legal requirements impacting data privacy and AI transparency within EMA’s remit.
- Investigate detailed terms of interaction between EMA, industry stakeholders, and data protection authorities to understand measures ensuring regulatory independence and privacy.
- Seek external expert or civil society analyses of EMA’s AI activities, focusing on privacy, bias, and ethical issues.
- Explore the specifics of the EMA-FDA guiding principles on AI, particularly how they address patient data rights and transparency.
- Monitor forthcoming EMA AI Observatory reports for emerging evidence on the practical implications of AI use in medicines regulation.
Readers interested in these topics are encouraged to consult the original EMA source and related EU regulatory documents for comprehensive context and ongoing developments.
Source & verification
Primary source: What's new · November 11, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…